Neurología

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estatus, etc.

1. A Study of Mood Symptoms in Epilepsy Patients

   Rochester, Minn.

   The purpose of this study is to track neuropsychiatric symptoms in patients with epilepsy.

2. Posterior Fossa Decompression with or without Duraplasty for Chiari Type I Malformation with Syringomyelia

   Rochester, Minn.

   The purpose of this study is to determine whether a posterior fossa decompression or a posterior fossa decompression with duraplasty results in better patient outcomes with fewer complications and improved quality of life in those who have Chiari malformation type I and syringomyelia.

3. A Study to Investigate the Safety and Tolerability of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents with Dravet Syndrome

   Rochester, Minn.

   The purpose of this study is to evaluate the safety and tolerability of single-ascending doses of STK-001 in patients with Dravet Syndrome.

4. Natural History Study Protocol in PMM2-CDG (CDG-Ia)

   Rochester, Minn.

   Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG) This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia). Data from this natural history study will be used to determine a set of clinical and biological parameters that will be used for primary and secondary endpoints in a later clinical trial with a new chemical entity, Lipo-M1P.

5. A Study to Evaluate Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Patients

   Rochester, Minn.

   The purpose of this study is to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims:

6. A Study to Evaluate Safety of Long-term AL001 Dosing in FTD Patients

   Rochester, Minn.

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AL001 in participants with a  frontotemporal dementia.

7. The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

   Rochester, Minn.

   The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing.

8. A Study to Validate Modified UMSARS Qualitative Research

   Rochester, Minn.

   The purpose of this study is to validate use of a modified Unified Multiple System Atrophy Rating Scale (UMSARS) that incorporates structured questions and additional instructions, developed by Biohaven Pharmaceuticals based on feedback from the FDA, as the primary outcome variable for assessing clinically meaningful change in Biohaven’s Phase 3 Multiple System Atrophy (MSA) Study BHV3241-301.

9. A Study to Evaluate Newly-diagnosed Idiopathic Generalized Epilepsy

   Rochester, Minn.

   The purpose of this study is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with newly-diagnosed idiopathic generalized epilepsy (IGE).

10. HEALEY ALS Platform Trial

    Jacksonville, Fla., Rochester, Minn.

    The purpose of this study is to evaluate the safety and effectiveness of investigational products for the treatment of ALS.